Copyright Reports & Markets. All rights reserved.

Global Recombinant Human Somatropin for Injection Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Recombinant Human Somatropin for Injection
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Recombinant Human Somatropin for Injection Consumption Value by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Powder Injection
    • 1.3.3 Aqueous Injection
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Recombinant Human Somatropin for Injection Consumption Value by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Hospital
    • 1.4.3 Clinic
    • 1.4.4 Others
  • 1.5 Global Recombinant Human Somatropin for Injection Market Size & Forecast
    • 1.5.1 Global Recombinant Human Somatropin for Injection Consumption Value (2018 & 2022 & 2029)
    • 1.5.2 Global Recombinant Human Somatropin for Injection Sales Quantity (2018-2029)
    • 1.5.3 Global Recombinant Human Somatropin for Injection Average Price (2018-2029)

2 Manufacturers Profiles

  • 2.1 Novo Nordisk
    • 2.1.1 Novo Nordisk Details
    • 2.1.2 Novo Nordisk Major Business
    • 2.1.3 Novo Nordisk Recombinant Human Somatropin for Injection Product and Services
    • 2.1.4 Novo Nordisk Recombinant Human Somatropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Novo Nordisk Recent Developments/Updates
  • 2.2 LG Chem
    • 2.2.1 LG Chem Details
    • 2.2.2 LG Chem Major Business
    • 2.2.3 LG Chem Recombinant Human Somatropin for Injection Product and Services
    • 2.2.4 LG Chem Recombinant Human Somatropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 LG Chem Recent Developments/Updates
  • 2.3 Pfizer
    • 2.3.1 Pfizer Details
    • 2.3.2 Pfizer Major Business
    • 2.3.3 Pfizer Recombinant Human Somatropin for Injection Product and Services
    • 2.3.4 Pfizer Recombinant Human Somatropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Pfizer Recent Developments/Updates
  • 2.4 Eli lilly
    • 2.4.1 Eli lilly Details
    • 2.4.2 Eli lilly Major Business
    • 2.4.3 Eli lilly Recombinant Human Somatropin for Injection Product and Services
    • 2.4.4 Eli lilly Recombinant Human Somatropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Eli lilly Recent Developments/Updates
  • 2.5 Merck
    • 2.5.1 Merck Details
    • 2.5.2 Merck Major Business
    • 2.5.3 Merck Recombinant Human Somatropin for Injection Product and Services
    • 2.5.4 Merck Recombinant Human Somatropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Merck Recent Developments/Updates
  • 2.6 Roche
    • 2.6.1 Roche Details
    • 2.6.2 Roche Major Business
    • 2.6.3 Roche Recombinant Human Somatropin for Injection Product and Services
    • 2.6.4 Roche Recombinant Human Somatropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Roche Recent Developments/Updates
  • 2.7 Changchun GeneScience Pharmaceutical
    • 2.7.1 Changchun GeneScience Pharmaceutical Details
    • 2.7.2 Changchun GeneScience Pharmaceutical Major Business
    • 2.7.3 Changchun GeneScience Pharmaceutical Recombinant Human Somatropin for Injection Product and Services
    • 2.7.4 Changchun GeneScience Pharmaceutical Recombinant Human Somatropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Changchun GeneScience Pharmaceutical Recent Developments/Updates
  • 2.8 Anhui Anke Biotechnology
    • 2.8.1 Anhui Anke Biotechnology Details
    • 2.8.2 Anhui Anke Biotechnology Major Business
    • 2.8.3 Anhui Anke Biotechnology Recombinant Human Somatropin for Injection Product and Services
    • 2.8.4 Anhui Anke Biotechnology Recombinant Human Somatropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Anhui Anke Biotechnology Recent Developments/Updates
  • 2.9 Shanghai United Cell Biotechnology
    • 2.9.1 Shanghai United Cell Biotechnology Details
    • 2.9.2 Shanghai United Cell Biotechnology Major Business
    • 2.9.3 Shanghai United Cell Biotechnology Recombinant Human Somatropin for Injection Product and Services
    • 2.9.4 Shanghai United Cell Biotechnology Recombinant Human Somatropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Shanghai United Cell Biotechnology Recent Developments/Updates
  • 2.10 Zhongshan Sinobioway Hygene Biomedicine
    • 2.10.1 Zhongshan Sinobioway Hygene Biomedicine Details
    • 2.10.2 Zhongshan Sinobioway Hygene Biomedicine Major Business
    • 2.10.3 Zhongshan Sinobioway Hygene Biomedicine Recombinant Human Somatropin for Injection Product and Services
    • 2.10.4 Zhongshan Sinobioway Hygene Biomedicine Recombinant Human Somatropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Zhongshan Sinobioway Hygene Biomedicine Recent Developments/Updates

3 Competitive Environment: Recombinant Human Somatropin for Injection by Manufacturer

  • 3.1 Global Recombinant Human Somatropin for Injection Sales Quantity by Manufacturer (2018-2023)
  • 3.2 Global Recombinant Human Somatropin for Injection Revenue by Manufacturer (2018-2023)
  • 3.3 Global Recombinant Human Somatropin for Injection Average Price by Manufacturer (2018-2023)
  • 3.4 Market Share Analysis (2022)
    • 3.4.1 Producer Shipments of Recombinant Human Somatropin for Injection by Manufacturer Revenue ($MM) and Market Share (%): 2022
    • 3.4.2 Top 3 Recombinant Human Somatropin for Injection Manufacturer Market Share in 2022
    • 3.4.2 Top 6 Recombinant Human Somatropin for Injection Manufacturer Market Share in 2022
  • 3.5 Recombinant Human Somatropin for Injection Market: Overall Company Footprint Analysis
    • 3.5.1 Recombinant Human Somatropin for Injection Market: Region Footprint
    • 3.5.2 Recombinant Human Somatropin for Injection Market: Company Product Type Footprint
    • 3.5.3 Recombinant Human Somatropin for Injection Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Recombinant Human Somatropin for Injection Market Size by Region
    • 4.1.1 Global Recombinant Human Somatropin for Injection Sales Quantity by Region (2018-2029)
    • 4.1.2 Global Recombinant Human Somatropin for Injection Consumption Value by Region (2018-2029)
    • 4.1.3 Global Recombinant Human Somatropin for Injection Average Price by Region (2018-2029)
  • 4.2 North America Recombinant Human Somatropin for Injection Consumption Value (2018-2029)
  • 4.3 Europe Recombinant Human Somatropin for Injection Consumption Value (2018-2029)
  • 4.4 Asia-Pacific Recombinant Human Somatropin for Injection Consumption Value (2018-2029)
  • 4.5 South America Recombinant Human Somatropin for Injection Consumption Value (2018-2029)
  • 4.6 Middle East and Africa Recombinant Human Somatropin for Injection Consumption Value (2018-2029)

5 Market Segment by Type

  • 5.1 Global Recombinant Human Somatropin for Injection Sales Quantity by Type (2018-2029)
  • 5.2 Global Recombinant Human Somatropin for Injection Consumption Value by Type (2018-2029)
  • 5.3 Global Recombinant Human Somatropin for Injection Average Price by Type (2018-2029)

6 Market Segment by Application

  • 6.1 Global Recombinant Human Somatropin for Injection Sales Quantity by Application (2018-2029)
  • 6.2 Global Recombinant Human Somatropin for Injection Consumption Value by Application (2018-2029)
  • 6.3 Global Recombinant Human Somatropin for Injection Average Price by Application (2018-2029)

7 North America

  • 7.1 North America Recombinant Human Somatropin for Injection Sales Quantity by Type (2018-2029)
  • 7.2 North America Recombinant Human Somatropin for Injection Sales Quantity by Application (2018-2029)
  • 7.3 North America Recombinant Human Somatropin for Injection Market Size by Country
    • 7.3.1 North America Recombinant Human Somatropin for Injection Sales Quantity by Country (2018-2029)
    • 7.3.2 North America Recombinant Human Somatropin for Injection Consumption Value by Country (2018-2029)
    • 7.3.3 United States Market Size and Forecast (2018-2029)
    • 7.3.4 Canada Market Size and Forecast (2018-2029)
    • 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

  • 8.1 Europe Recombinant Human Somatropin for Injection Sales Quantity by Type (2018-2029)
  • 8.2 Europe Recombinant Human Somatropin for Injection Sales Quantity by Application (2018-2029)
  • 8.3 Europe Recombinant Human Somatropin for Injection Market Size by Country
    • 8.3.1 Europe Recombinant Human Somatropin for Injection Sales Quantity by Country (2018-2029)
    • 8.3.2 Europe Recombinant Human Somatropin for Injection Consumption Value by Country (2018-2029)
    • 8.3.3 Germany Market Size and Forecast (2018-2029)
    • 8.3.4 France Market Size and Forecast (2018-2029)
    • 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
    • 8.3.6 Russia Market Size and Forecast (2018-2029)
    • 8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

  • 9.1 Asia-Pacific Recombinant Human Somatropin for Injection Sales Quantity by Type (2018-2029)
  • 9.2 Asia-Pacific Recombinant Human Somatropin for Injection Sales Quantity by Application (2018-2029)
  • 9.3 Asia-Pacific Recombinant Human Somatropin for Injection Market Size by Region
    • 9.3.1 Asia-Pacific Recombinant Human Somatropin for Injection Sales Quantity by Region (2018-2029)
    • 9.3.2 Asia-Pacific Recombinant Human Somatropin for Injection Consumption Value by Region (2018-2029)
    • 9.3.3 China Market Size and Forecast (2018-2029)
    • 9.3.4 Japan Market Size and Forecast (2018-2029)
    • 9.3.5 Korea Market Size and Forecast (2018-2029)
    • 9.3.6 India Market Size and Forecast (2018-2029)
    • 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
    • 9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

  • 10.1 South America Recombinant Human Somatropin for Injection Sales Quantity by Type (2018-2029)
  • 10.2 South America Recombinant Human Somatropin for Injection Sales Quantity by Application (2018-2029)
  • 10.3 South America Recombinant Human Somatropin for Injection Market Size by Country
    • 10.3.1 South America Recombinant Human Somatropin for Injection Sales Quantity by Country (2018-2029)
    • 10.3.2 South America Recombinant Human Somatropin for Injection Consumption Value by Country (2018-2029)
    • 10.3.3 Brazil Market Size and Forecast (2018-2029)
    • 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

  • 11.1 Middle East & Africa Recombinant Human Somatropin for Injection Sales Quantity by Type (2018-2029)
  • 11.2 Middle East & Africa Recombinant Human Somatropin for Injection Sales Quantity by Application (2018-2029)
  • 11.3 Middle East & Africa Recombinant Human Somatropin for Injection Market Size by Country
    • 11.3.1 Middle East & Africa Recombinant Human Somatropin for Injection Sales Quantity by Country (2018-2029)
    • 11.3.2 Middle East & Africa Recombinant Human Somatropin for Injection Consumption Value by Country (2018-2029)
    • 11.3.3 Turkey Market Size and Forecast (2018-2029)
    • 11.3.4 Egypt Market Size and Forecast (2018-2029)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
    • 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

  • 12.1 Recombinant Human Somatropin for Injection Market Drivers
  • 12.2 Recombinant Human Somatropin for Injection Market Restraints
  • 12.3 Recombinant Human Somatropin for Injection Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Recombinant Human Somatropin for Injection and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Recombinant Human Somatropin for Injection
  • 13.3 Recombinant Human Somatropin for Injection Production Process
  • 13.4 Recombinant Human Somatropin for Injection Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Recombinant Human Somatropin for Injection Typical Distributors
  • 14.3 Recombinant Human Somatropin for Injection Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Recombinant Human Somatropin for Injection market size was valued at USD 2485.9 million in 2022 and is forecast to a readjusted size of USD 3151.1 million by 2029 with a CAGR of 3.4% during review period.
    Recombinant Human Somatropin, commonly known as somatropin or human growth hormone (hGH), is a synthetic form of the growth hormone produced naturally in the human body. Somatropin is created using recombinant DNA technology, and it is structurally identical to the growth hormone secreted by the pituitary gland. It is used for various medical and non-medical purposes.
    Recombinant Human Somatropin for Injection is a widely used biopharmaceutical in the medical field, primarily employed in the treatment of growth hormone deficiency, short stature, muscle wasting, and related conditions. The market size is substantial, driven by ongoing concerns related to endocrine and growth issues in both children and adults. Sales of the product have steadily increased over the years and are expected to continue to show potential in the future, particularly with the introduction of new therapeutic applications and improved delivery methods, such as enhanced injection devices. Furthermore, as medical science and technology continue to advance, recombinant human somatropin may find applications in a broader spectrum of health fields, creating more opportunities for its future development.
    The Global Info Research report includes an overview of the development of the Recombinant Human Somatropin for Injection industry chain, the market status of Hospital (Powder Injection, Aqueous Injection), Clinic (Powder Injection, Aqueous Injection), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Recombinant Human Somatropin for Injection.
    Regionally, the report analyzes the Recombinant Human Somatropin for Injection markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Recombinant Human Somatropin for Injection market, with robust domestic demand, supportive policies, and a strong manufacturing base.
    Key Features:
    The report presents comprehensive understanding of the Recombinant Human Somatropin for Injection market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Recombinant Human Somatropin for Injection industry.
    The report involves analyzing the market at a macro level:
    Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Powder Injection, Aqueous Injection).
    Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Recombinant Human Somatropin for Injection market.
    Regional Analysis: The report involves examining the Recombinant Human Somatropin for Injection market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
    Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Recombinant Human Somatropin for Injection market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
    The report also involves a more granular approach to Recombinant Human Somatropin for Injection:
    Company Analysis: Report covers individual Recombinant Human Somatropin for Injection manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
    Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Recombinant Human Somatropin for Injection This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).
    Technology Analysis: Report covers specific technologies relevant to Recombinant Human Somatropin for Injection. It assesses the current state, advancements, and potential future developments in Recombinant Human Somatropin for Injection areas.
    Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Recombinant Human Somatropin for Injection market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
    Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
    Market Segmentation
    Recombinant Human Somatropin for Injection market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
    Market segment by Type
    Powder Injection
    Aqueous Injection
    Market segment by Application
    Hospital
    Clinic
    Others
    Major players covered
    Novo Nordisk
    LG Chem
    Pfizer
    Eli lilly
    Merck
    Roche
    Changchun GeneScience Pharmaceutical
    Anhui Anke Biotechnology
    Shanghai United Cell Biotechnology
    Zhongshan Sinobioway Hygene Biomedicine
    Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Recombinant Human Somatropin for Injection product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Recombinant Human Somatropin for Injection, with price, sales, revenue and global market share of Recombinant Human Somatropin for Injection from 2018 to 2023.
    Chapter 3, the Recombinant Human Somatropin for Injection competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Recombinant Human Somatropin for Injection breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
    Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Recombinant Human Somatropin for Injection market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
    Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Recombinant Human Somatropin for Injection.
    Chapter 14 and 15, to describe Recombinant Human Somatropin for Injection sales channel, distributors, customers, research findings and conclusion.

    Buy now